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Cardiac 2-[F-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography
(PET) has been regarded as the gold standard for interpreting myocardial
viability,
1,2 and it is an especially important tool for predicting improvements in
cardiac function after revascularization therapies for patients with myocardial
ischemic events.
3 A sustained uptake of FDG accompanied by reduced perfusion
(metabolism-perfusion mismatch) is considered to be an indicator of ischemic but
viable myocardium. Low uptake of FDG suggests a decrease in glucose utiliza-
tion due to ischemic insult and is considered to be an indicator of either viable or
not viable myocardium depending on the severity the of defect in FDG uptake.
For example, a myocardial FDG uptake of less than 50% of the normal uptake
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Purpose: In cardiac 2-[F-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) examination,
interpretation of myocardial viability in the low uptake region (LUR) has been difficult without additional perfusion
imaging. We evaluated distribution patterns of FDG at the border zone of the LUR in the cardiac FDG-PET and
established a novel parameter for diagnosing myocardial viability and for discriminating the LUR of normal
variants. Materials and Methods: Cardiac FDG-PET was performed in patients with a myocardial ischemic event
(n = 22) and in healthy volunteers (n = 22). Whether the myocardium was not a viable myocardium (not-VM) or an
ischemic but viable myocardium (isch-VM) was defined by an echocardiogram under a low dose of dobutamine
infusion as the gold standard. FDG images were displayed as gray scaled-bull’s eye mappings. FDG-plot profiles
for LUR (= true ischemic region in the patients or normal variant region in healthy subjects) were calculated.
Maximal values of FDG change at the LUR border zone (a steepness index; Smax scale/pixel) were compared among
not-VM, isch-VM, and normal myocardium. Results: Smax was significantly higher for n-VM compared to those
with isch-VM or normal myocardium (ANOVA). A cut-off value of 0.30 in Smax demonstrated 100% sensitivity
and 83% specificity for diagnosing n-VM and isch-VM. Smax less than 0.23 discriminated LUR in normal
myocardium from the LUR in patients with both n-VM and isch-VM with a 94% sensitivity and a 93% specificity.
Conclusion: Smax of the LUR in cardiac FDG-PET is a simple and useful parameter to diagnose n-VM and isch-
VM, as well as to discriminate thr LUR of normal variants.
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INTRODUCTIONvalue is one of the criteria to indicate a not viable myocar-
dium.
4-6 The extent of lower uptake of FDG is qualitatively
expressed as mild, moderate, or severe compared to back-
ground and other myocardial regions.
7,8 However, it has
been difficult to interpret whether the myocardium is viable
or not viable without information from perfusion imaging.
2
Another limitation of cardiac FDG-PET is the spatial and
temporal heterogeneity of the uptake distributions in nor-
mal myocardium
9 that are recognized as normal variants.
10,11
Whether a low uptake region indicates a physiological
modification or a pathological perturbation is one, it needs
to be differentiated in order to avoid false-positive results.
Therefore, it is necessary to establish a novel diagnostic
parameter to interpret low uptake regions of cardiac FDG
without additional perfusion imaging in order to discrimi-
nate the three different myocardial conditions: normal
variant, ischemic but viable myocardium, and not viable
myocardium.  
In the present study, we hypothesized that distribution of
the FDG at the border zone of a low uptake region demons-
trated characteristics specific to the normal myocardium,
ischemic but viable myocardium, and not viable myocar-
dium conditions that can be used to discriminate one from
another. To verify our hypothesis, we examined cardiac
FDG-PET in healthy volunteers and in patients with myo-
cardial ischemic event. In the latter, viability of the myocar-
dium at the culprit lesion was defined by an echocardio-
gram at rest and under low dose-dobutamine stress.
Patient population was further divided into two groups:
those with ischemic but viable myocardium, and those with
not viable myocardium. By converting FDG-PET data to a
gray scale bull’s eye mapping, we were able to evaluate a
novel index expressing the steepness of FDG distribution
at the border zone of the low uptake region (Smax). We
report in the present study that cut-off values of Smax can be
used to discriminate normal myocardium, ischemic but
viable myocardium, and not viable myocardium with high
sensitivity and high specificity.  
Study population and conditioning of the subjects  
The study population was comprised of 22 patients with
myocardial ischemic events (patient group; range, 53-80
years, mean ± SD: 71.1 ± 7.5 years, 18 males, 4 females)
and 22 healthy volunteers (healthy group: range, 19-22
years, mean ± SD: 20.5 ± 0.7 years, 10 males, 12 females).
Patients with myocardial ischemic events who were hospi-
talized and had cardiac catheterization were also enrolled.
The present study began more than one month after acute
on-set of the ischemic event or the last revascularization
therapy. In the healthy group, the inclusion criteria included
normal physical examination, normal resting electrocar-
diogram, normal echocardiogram, and lack of a past history
of cardiac disease or any chronic diseases. Detailed infor-
mation of the patients and healthy volunteers are shown in
Tables 1 and 2, respectively.  
Both the control and the patient groups were further
divided into two subgroups: those under fasting conditions
and those under glucose loading conditions before FDG
administration. In the former, the fasting condition was
maintained 6 to 7 hours after meals (two rice balls and
plum pickles and green tea). In the latter, 6 to 7 hours of the
fasting was maintained followed by an oral administration
of glucose (75 g) solution 60 minutes before a FDG in-
jection.  
This study was approved by the Research Ethics Com-
mittee of Kawasaki Medical School (No. 295). Each subject
gave written consent before participating in the study.  
FDG-PET/CT scan
18F-FDG of 185MBq (FDGscan In jectable, Nihon Medi-
physics, Tokyo, Japan) was administered intravenously. At
115 minutes after FDG administration, a transmission scan
was performed using a Discovery ST Elite (GE Health-
care, Piscataway, NJ, USA) under the following conditions:
5 minutes data acquisition, 128×128 matrix size, 3.3 mm
slice width, 47 slices, and attenuation correction using CT.    
Image processing  
Acquired FDG images were reconstructed using 3D-
OSEM (VEU point) under the following conditions: 3.59
mm post filter, 3.59 mm FWHM, 28 subset, and 2 iterations.
Short axis view of the heart was converted to DICOM data
using Daemon Research Image Processor (version 1.0.3.4,
Fuji Film Pharma, Co. Ltd., Tokyo, Japan) and displayed as
colored bull’s eye mapping using CardioBull (version 3.0,
Fuji Film Pharma). The identical bull’s eye mapping was
redisplayed with 256-gray scale. Referring to the colored
bull’s eye mapping and patient database (electrocardiogram,
echocardiogram, and cardiac catheterization), the location
of the culprit region in the gray scale bull’s eye mapping
was confirmed. Including the culprit region (area of ischemic
event) and neighboring non-culprit region, the plot profile
(a gray scale-slope) along the optional line was scanned to
find the point where the gray scale slope was the steepest
(Scion Image, ALPHA4.0.3.2, Scion Corporation, Frederick,
Maryland, USA).  The steepness of the gray scale slope at
the optional pixel point was analyzed by the change in gray
scale per pixel.  Maximal steepness was analyzed by the
absolute value of change in gray scale per pixel (Smax; scale/
pixel) which was manually detected since automatic detec-
tion algorithm has not developed yet. Almost of all of the
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.maximal values (Smax point) were found around the line
connecting the minimal FDG count (in the culprit lesion)
and neighboring high FDG count in the bull’s eye map-
ping. In the healthy group, the Smax was determined by the
same procedure. The lowest FDG uptake region was includ-
ed instead of an area of the ischemic event. This analysis
was performed by two independent investigators.  
Since the total amount of cardiac FDG uptake is known
to be critical for interpreting the cardiac FDG-PET find-
ings,
12 FDG count of the left ventricle was evaluated by
comparing it to the background. One ROI was placed to
include the whole left ventricle and another ROI in the
right lung field (as back ground) in the serial transaxial
images (Daemon Research Image Processor, version
1.0.3.4, Fuji Film Pharma). Maximal count in the left vent-
ricle divided by maximal count in the lung (Hmax/Lmax) was
calculated. We assumed in the present study that sufficient
cardiac uptake was defined by Hmax/Lmax ≥ 10.0, and insuf-
ficient if HHmax/Lmax < 10.0.  
Comparative study by echocardiogram 
Whether the area demonstrating low uptake region in
FDG-PET (area of interest) was not viable myocardium or
ischemic but viable myocardium was defined by echocar-
diogram (SONOS 7500, Phillips, Amsterdam, The Nether-
lands) at rest and under low-dobutamine stress. If the area
of interest showed normal or hypokinetic wall motion at
rest, this region was defined as ischemic but viable. If the
area of interest was akinetic or showed dyskinetic wall
motion at rest, echocardiogram was evaluated under low
dose (5 to 10 µg/kg/minute) dobutamine infusion. If im-
provement in the wall motion was observed, this region
was defined as ischemic but viable myocardium.
13 If not,
then it was defined as not viable myocardium. The viability
was diagnosed by agreement from two echo-cardiologists.   
Statistical analysis  
All data is expressed as the mean ± SD.  The differences in
values were evaluated by one way-ANOVA, followed by
Fisher’s PLSD. The sensitivity and specificity of the cut-
off value of Smax was evaluated by qui-square test. The
inter-observer agreement was assessed by determining the
mean and SD of the between observation difference. A p
value less than 0.05 was considered statistically significant.  
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Table 2. Healthy Volunteers’ Profile and Findings of Echocardiogram and FDG-PET
Echocardiogram FDG-PET
No. Age Sex
Viability
Glucose  
Hmax/Lmax
Low uptake  Smax
conditioning region (scale / pixel)
1 21 F Viable Loading 34.6 Present 0.22 
2 21 M Viable Loading 25.7 Present 0.16 
3 20 M Viable Loading 29.0 Present 0.13 
4 20 M Viable Loading 41.7 Present 0.17 
5 20 F Viable Loading 30.7 Present 0.16 
6 21 F Viable Loading 35.1 Present 0.20 
7 21 M Viable Loading 34.8 Present 0.21 
8 21 F Viable Loading 55.9 Absent 0.10 
9 21 F Viable Loading 24.2 Present 0.27 
10 21 F Viable Fasting 5.4 Present 0.15 
11 21 M Viable Fasting 29.3 Present 0.19 
12 20 F Viable Fasting 15.8 Present 0.19 
13 21 M Viable Fasting 8.2 Present 0.30 
14 19 F Viable Fasting 8.6 Present 0.19 
15 20 F Viable Fasting 13.5 Present 0.21 
16 20 M Viable Fasting 8.0 Present 0.30 
17 21 F Viable  Fasting 3.5 (Reconstruction failure) N / A
18 22 M Viable Fasting 9.6 Present 0.22 
19 21 F Viable  Fasting 3.9 (Reconstruction failure) N / A
20 20 M Viable Fasting 15.0 Present 0.22 
21 20 F Viable Fasting 71.8 Absent 0.13 
22 20 M Viable Fasting 21.1 Present 0.22 Echocardiographic study defined ten patients with ischemic
but viable myocardium and 12 patients with not viable
myocardium. Twenty FDG sets of data were evaluated as
normal myocardium in the healthy group. Two healthy
volunteers (under fasting condition) were not included in
the final analysis as they showed FDG uptake levels that
were too low to reconstruct images. The same failure occur-
red in one patient with not viable myocardium. Thus, 11
sets of FDG data were evaluated as not viable myocardium.
One patient with ischemic but viable myocardium showed
extremely high FDG uptake (typical case of metabolism-
perfusion mismatch). This case was also excluded because
we only focused on evaluating the clinical significance of
low FDG uptake in the present study. Thus, nine FDG
patients were evaluated as ischemic but viable myocardium. 
Representative images of bull’s eye mapping of FDG-
PET are shown in Fig. 1A. Both the patients with myocar-
dial ischemic events as well as the healthy volunteers
showed low uptake regions. Almost all of the healthy volun-
teers showed heterogeneous distribution. Single or multiple
low uptake region(s) were observed in 89% of subjects
under glucose loading and 92% of subjects under fasting
(Table 2). Thus, the finding of low uptake region per se is
not likely to be a diagnostic parameter.  
Fig. 1B demonstrates the plot profile of the FDG distri-
bution using the gray scale mapping in Fig. 1A. Steepness
of the FDG-gray scale change (Fig. 1C) was higher in the
ischemic patient group (absolute values of Smax are 0.58 and
0.53 scale/pixel) than that in the healthy volunteers (absolute
values of Smax are 0.22 and 0.30 scale/pixel).   
Hmax/Lmax, the parameter for global myocardial FDG
uptake, is high (assumed sufficient in the present study) in
patient #15 (15.4) and healthy volunteer #20 (15.0), but
low in patient #20 (6.3) and in healthy volunteer #16 (8.0,
Fig. 1D). Thus, the Smax is feasible for use in interpreta-
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Fig. 1. Representative images of cardiac FDG-PET and Smax in patients with myocardial ischemic event as well as healthy volunteers. Myocardium in patient #17 was
defined as viable by an echocardiogram under low dose of dobutamine stress. Myocardium in patient #15 and #20 were defined as not viable. (A) FDG bull’s eye
mapping (colored and gray scaled). Low uptake regions were observed in both patients (#17, #15, and #20) and healthy volunteers (#20 and #16). (B) FDG plot profile
along white and blue lines in the panel A. (C) Changing rate of FDG gray scale per pixel along the line. Absolute values (red) indicate Smax values. The pink dots in the
panels A, B, and C indicate the location of Smax. (D) Hmax /Lmaxvalues are shown. FDG, cardiac 2-[F-18] fluoro-2-deoxy-D-glucose; PET, positron emission tomegraphy.
AB C Dtions for patient #15 and healthy volunteer #20, but not for
patient #20 and for healthy volunteer #16. A patient with
ischemic but viable myocardium, patient #17, showed high
enough Hmax/Lmax (18.1) and a low absolute value of Smax
(0.19).       
The Smax values from subjects with Hmax/Lmax ≥ 10 were
selected and analyzed. The Smax was significantly different
between three myocardial conditions (p< 0.0001, ANOVA)
(Fig. 2). The Smax in the not viable myocardium (0.42 ±
0.10 scale/pixel) was significantly higher than that in the
normal myocardium (0.19 ± 0.04 scale/pixel, p < 0.0001) as
well as that in the ischemic but viable myocardium (0.25 ±
0.05 scale/pixel, p < 0.0001). The Smax in the ischemic but
viable myocardium was higher than that in normal myocar-
dium (p = 0.03). In the patient group, a cut-off value of 0.30
scale/pixel differentiated not viable myocardium from
ischemic but viable myocardium with 100% sensitivity and
71% specificity.  This indicated that 0.30 scale/pixel in the
Smax is a useful parameter to estimate myocardial viability.
Overall, a cut-off value of 0.23 scale/pixel differentiated
the patient group (not viable myocardium + ischemic but
viable myocardium) from the healthy group with 88%
sensitivity and 93% specificity. This cut-off value was also
useful in detecting patients with myocardial ischemic event
(not viable myocardium or ischemic but viable myocardium)
in an optional population. However, this sensitivity and
specificity were slightly decreased to 85% and 85%,
respectively, if the subjects’ data with Hmax/Lmax less than 10
were included in the analysis.  
Inter-observer difference was low for measurement of
Smax (Fig. 3). The correlation coefficient was high for meas-
urements by two different observers (r = 0.97).   
Diagnosis of myocardial viability and discrimination of
normal variants in FDG-PET examination have previously
been considered difficult without additional information
from perfusion imaging. The major reason is the spatial
and temporal heterogeneity in FDG distribution along with
the low uptake regions that are observed in patients with
ischemic but viable myocardium and even in healthy sub-
jects. In the present study, we established a novel and simple
numerical parameter of cardiac FDG-PET to diagnose not
viable myocardium as well as ischemic but viable myocar-
dium, and also to discriminate normal variants. In the
selected subjects with sufficient uptake of myocardial
FDG (Hmax/Lmax ≥ 10), the index of maximal steepness of
FDG uptake gray scale slope at the border zone of the low
uptake region in the bull’s eye mapping (Smax) was signi-
ficantly different for these three conditions. The Smax in the
not viable myocardium (defined by echocardiogram at rest
Novel Parameter of Myocardial Viability by FDG-PET
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Fig. 2. Difference of Smax in three myocardial conditions. The Smax is the highest
in the not viable myocardium (red circles), intermediate in ischemic but viable
myocardium (brown circles), and the lowest in normal myocardium (blue
circles). Closed circles and solid lines (mean ± SD): data from the subjects with
Hmax/Lmax≥10. Open circles: data of the subjects with Hmax/Lmax< 10. Dashed lines
(mean ±SD) were analyzed by including all data (both Hmax/Lmax≥10 and < 10). 
Fig. 3.Inter-observer variability of Smaxvalues.  
DISCUSSIONand under low dose dobutamine stress) was distributed at a
higher range (0.42 ± 0.10 scale/pixel). The Smax in the
ischemic but viable myocardium distributed at an interme-
diate range (0.25 ± 0.05 scale/pixel). The Smax in the normal
variant distributed at a lower range (0.19 ± 0.04 scale/pixel).
In the patient group with myocardial ischemic events, the
cut-off value of 0.30 scale/pixel differentiated not viable
myocardium from ischemic but viable myocardium with
100% sensitivity and 71% specificity, indicating the useful-
ness of Smax to diagnose myocardial viability after the
myocardial ischemic event. Overall, a cut-off value of 0.23
scale/pixel differentiated the patient group (≥ 0.23) from
the normal group (< 0.23) with 88% sensitivity and 93%
specificity, indicating the usefulness of Smax to detect patients
with a myocardial ischemic event (myocardium is viable
or not viable) within an optional population. We concluded
that the Smax in the FDG-PET is a novel parameter to dia-
gnose myocardial viability without additional information
from perfusion imaging and also a tool to discriminate
normal variants of FDG distribution.  
We attributed the significant differences in Smax values
among not viable myocardium, ischemic but viable myocar-
dium, and normal variant populations to partial volume
effect as limited by spatial resolution of the PET (voxel
size of the scanner: 3.3×3.3×3.3 mm
3 in the present
study). Optional point in the bull’s eye mapping (X-Y axes
plane) is converted to display the mean FDG count along
the transmural direction (Z-axis; ~10 mm depth). We con-
sidered that the real distribution of FDG along transmural
wall is different for these three conditions, as shown in the
schematic diagram in Fig. 4. After a myocardial ischemic
event, a partition of glucose utilization increases, but even-
tually disappears depending on the severity of the ischemic
insult. If the ischemic insult is severe, the not viable myocar-
dium (lack of FDG uptake) occupies the wall transmurally
with a relatively clear border. Thus, the Smax would be high
in this case. If the ischemic insult is mild, the not viable
myocardium is limited to the subendocardial layer. Also,
small clusters of the ischemic area
14 heterogeneously
distributed in the transmural wall
15 may merge together.
16
The borderline may be relatively unclear, and thus the Smax
would be lower than that in the not viable myocardium.
Glucose utilization in these myocardial conditions is pathol-
ogically disrupted, and the presence of these conditions
must lead to different glucose utilization in physiological
modification in normal subjects (normal variant). Although
the mechanisms of physiological modification of glucose
utilization (its control unit size of and mechanism of spatial/
temporal heterogeneity etc.) are still unclear,
17 we believe
that the appearance of a decreased glucose utilization along
the transmural wall as a normal variant is different from
that in pathological disruption of glucose utilization due to
ischemic insults. This speculation may be supported by the
lowest Smax value in the normal variant. Further investi-
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Myocardial
wall
Fig. 4.Schematic diagram of real FDG uptake in the myocardial wall and FDG-PET count. Gray area: positive FDG uptake. White area: negative FDG uptake. Voxel size
of the PET scanner in the present study was 3.3×3.3×3.3 mm
3. FDG count is displayed as its average of that in the transmural wall. Steepness of the FDG slope at the
border zone of the low uptake region is different for not viable myocardium, ischemic but viable myocardium, and normal variant (speculated). FDG, cardiac 2-[F-18]
fluoro-2-deoxy-D-glucose; PET, positron emission tomegraphy.gation is required to confirm this hypothesis.  
A perfusion image (i.e., 
201Tl-Cl and 
13N ammonia scinti-
gram etc.) is compared to metabolic assessment by myo-
cardial FDG-PET to interpret myocardial viability.  Ameri-
can Society of Nuclear Cardiology Practice Guidelines in
2003 noted that interpretation of FDG images without
perfusion imaging information is considered to be difficult
and unreliable for distinguishing normal myocardium from
irreversibly injured myocardium.
2 However, the present
study showed that the myocardial FDG-PET enabled us to
distinguish these myocardial conditions without additional
perfusion imaging by analyzing the Smax in FDG-PET.
Using this method, we were able to diagnose not viable
myocardium (≥ 0.30 scale/pixel) and ischemic but viable
myocardium (< 0.30 scale/pixel) in the patient group and
also to discriminate normal myocardium (normal variant, <
0.23 scale/pixel) from the patient group with high sensitivity
and high specificity if there was sufficient global cardiac
FDG uptake (Hmax/Lmax ≥ 10.0). We do not, however, believe
that a perfusion image is unnecessary in evaluating myo-
cardial viability. One case showed extremely high uptake of
FDG at the ischemic area and was readily interpreted as
viable myocardium with an additional 
201Tl-Cl perfusion
imaging (but this case was excluded from the present study
because we primarily focused on the significance of Smax in
cases with low uptake region of FDG).  
Glucose loading of the subjects has been previously
recommended
18 to increase unitization of glucose by the
myocardium and to improve diagnostic accuracy of cardiac
FDG-PET.
12 However, it was insufficient to erase the
heterogeneities in FDG distribution in the present study as
89% of the healthy group under glucose loading had
assumed heterogeneous distribution of FDG (Table 2).
Nonetheless, glucose loading was effective in increasing
global FDG uptake into the myocardium
19 (increases in
probability to satisfy the condition of Hmax/Lmax ≥ 10.0) and
helped improve validity of Smax. Note that fasting condi-
tions allowed interpretation of myocardial viability by Smax
as long as the subject showed sufficient global myocardial
FDG uptake (Hmax/Lmax ≥ 10.0, 46% of the healthy volun-
teer and 86% of the patients satisfy this criteria under
fasting conditions in the present study). Data selection
according to the criteria of Hmax/Lmax ≥ 10.0 assisted in eval-
uating Smax despite glycemic conditioning. Our recom-
mended strategies to diagnose myocardial viability using
FDG-PET and Smax, as well as discrimination of normal
variant are shown in Fig. 5.  
In terms of study limitations, the number of the patients
with identical glucose conditioning is still small in the
present study. A strict criteria of ischemic conditions may be
further required. Additional perfusion imaging study may
help the conclusion. A larger scale longitudinal study on
whether Smax predicts the extent of functional recovery by
revascularization therapy as well as the patient prognosis is
required. To do this, an automatic program to calculate the
Smax would be needed.  
In conclusion, the Smax in cardiac FDG-PET bull’s eye
mapping is a simple and useful numerical parameter with
high sensitivity and high specificity to diagnose myocardial
viability (not viable myocardium if cut-off value ≥ 0.30
scale/pixel) and to discriminate normal variants (if cut-off
value < 0.23 scale/pixel). Additional perfusion imaging is
supportive, but not indispensable, if the Smax is evaluated
under the condition of Hmax/Lmax ≥ 10. Glucose loading is
recommended to obtain higher probability of Hmax/Lmax ≥
10, but not necessary as long as the patients satisfy the
criteria of Hmax/Lmax ≥10 when fasting.  
This study was supported by a Kawasaki Medical School
Research Grant for Faculty.  
1. Baumgartner H, Porenta G, Lau YK, Wutte M, Klaar U, Mehrabi
M, et al. Assessment of myocardial viability by dobutamine
echocardiography, positron emission tomography and thallium-
201 SPECT: correlation with histopathology in explanted hearts.
J Am Coll Cardiol 1998;32:1701-8.
2. Schelbert HR, Beanlands R, Bengel F, Knuuti J, Dicarli M,
Machac J, et al. PET myocardial perfusion and glucose metabolism
imaging: Part 2-Guidelines for interpretation and reporting. J
Nucl Cardiol 2003;10:557-71.
3. Bax JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici PG.
Accuracy of PET in predicting functional recovery after revas-
cularisation in patients with chronic ischaemic dysfunction: head-
to-head comparison between blood flow, glucose utilisation and
water-perfusable tissue fraction. Eur J Nucl Med Mol Imaging
2002;29:721-7.
Novel Parameter of Myocardial Viability by FDG-PET
Yonsei Med J   http://www.eymj.org    Volume 51   Number 2   March 2010 185
Fig. 5. Diagram of strategy to diagnose myocardial viability and discrimination of
normal variant.  
ACKNOWLEDGEMENTS
REFERENCES4. Knuuti MJ, Nuutila P, Ruotsalainen U, Teräs M, Saraste M,
Härkönen R, et al. The value of quantitative analysis of glucose
utilization in detection of myocardial viability by PET. J Nucl
Med 1993;34:2068-75.
5. Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie
ER, et al. Predictive value of low dose dobutamine transesopha-
geal echocardiography and fluorine-18 fluorodeoxyglucose posi-
tron emission tomography for recovery of regional left ventricular
function after successful revascularization. J Am Coll Cardiol
1996;28:60-9.
6. Altehoefer C, Kaiser HJ, Dörr R, Feinendegen C, Beilin I, Uebis
R, et al. Fluorine-18 deoxyglucose PET for assessment of viable
myocardium in perfusion defects in 99mTc-MIBI SPET: a com-
parative study in patients with coronary artery disease. Eur J Nucl
Med 1992;19:334-42.
7. Porenta G, Kuhle W, Czernin J, Ratib O, Brunken RC, Phelps
ME, et al. Semiquantitative assessment of myocardial blood flow
and viability using polar map displays of cardiac PET images. J
Nucl Med 1992;33:1628-36.
8. Nekolla SG, Miethaner C, Nguyen N, Ziegler SI, Schwaiger M.
Reproducibility of polar map generation and assessment of defect
severity and extent assessment in myocardial perfusion imaging
using positron emission tomography. Eur J Nucl Med 1998;25:
1313-21.
9. Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo
P, et al. Spatial and temporal heterogeneity of regional myocar-
dial uptake in patients without heart disease under fasting condi-
tions on repeated whole-body 18F-FDG PET/CT. J Nucl Med
2007;48:1662-9.
10. Choi Y, Brunken RC, Hawkins RA, Huang SC, Buxton DB, Hoh
CK, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-
D-glucose uptake in positron emission tomography studies of
normal humans. Eur J Nucl Med 1993;20:308-18.
11. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Berg-
mann SR, et al. Nonuniformity in myocardial accumulation of
fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl
Med 1990;31:1749-56.
12. Schelbert HR. 18F-deoxyglucose and the assessment of myocar-
dial viability. Semin Nucl Med 2002;32:60-9.
13. Sawada S, Elsner G, Segar DS, O’Shaughnessy M, Khouri S,
Foltz J, et al. Evaluation of patterns of perfusion and metabolism
in dobutamine-responsive myocardium. J Am Coll Cardiol 1997;
29:55-61.
14. Ince C, Ashruf JF, Avontuur JA, Wieringa PA, Spaan JA, Bruin-
ing HA. Heterogeneity of the hypoxic state in rat heart is deter-
mined at capillary level. Am J Physiol 1993;264:H294-301.
15. Matsumoto T, Goto M, Tachibana H, Ogasawara Y, Tsujioka K,
Kajiya F. Microheterogeneity of myocardial blood flow in rabbit
hearts during normoxic and hypoxic states. Am J Physiol 1996;
270:H435-41.
16. Watanabe N, Akasaka T, Toyota E, Fujimoto K, Kajita T, Shigeto
F, et al. Three-dimensional microstructural abnormality of the
coronary capillary network after myocardial reperfusion--
comparison between ‘reflow’ and ‘no-reflow’. Circ J 2004;68:
868-72.
17. Deussen A. Local myocardial glucose uptake is proportional to,
but not dependent on blood flow. Pflugers Arch 1997;433:488-96.
18. Bacharach SL, Bax JJ, Case J, Delbeke D, Kurdziel KA, Martin
WH, et al. PET myocardial glucose metabolism and perfusion
imaging: Part 1-Guidelines for data acquisition and patient
preparation. J Nucl Cardiol 2003;10:543-56.
19. Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel
JH, et al. Optimal metabolic conditions during fluorine-18 fluoro-
deoxyglucose imaging; a comparative study using different
protocols. Eur J Nucl Med 1997;24:35-41.
Eiji Toyota, et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 2   March 2010 186